KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Non-Current Debt (2017 - 2025)

Novartis Ag (NVS) has disclosed Non-Current Debt for 9 consecutive years, with $27.9 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 30.75% to $27.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.9 billion through Dec 2025, up 30.75% year-over-year, with the annual reading at $27.9 billion for FY2025, 30.75% up from the prior year.
  • Non-Current Debt hit $27.9 billion in Q4 2025 for Novartis Ag, up from $21.4 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $27.9 billion in Q4 2025 to a low of $18.4 billion in Q4 2023.
  • Historically, Non-Current Debt has averaged $22.2 billion across 5 years, with a median of $21.4 billion in 2024.
  • Biggest five-year swings in Non-Current Debt: fell 12.78% in 2021 and later surged 30.75% in 2025.
  • Year by year, Non-Current Debt stood at $22.9 billion in 2021, then decreased by 11.61% to $20.2 billion in 2022, then fell by 8.93% to $18.4 billion in 2023, then rose by 15.89% to $21.4 billion in 2024, then soared by 30.75% to $27.9 billion in 2025.
  • Business Quant data shows Non-Current Debt for NVS at $27.9 billion in Q4 2025, $21.4 billion in Q4 2024, and $18.4 billion in Q4 2023.